Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinomaRuiqi Liu, Tongsen Zheng, Jiabei Wang et al.|Cancer Letters|2018Cited by 144
Benefit of Sunitinib in the treatment of pulmonary primitive neuroectodermal tumors: a case report and literature reviewChunhui Zhang, Yanqiao Zhang, Jingchun Zhang et al.|Oncotarget|2016Cited by 7